Logo image of ALCOX.PA

NICOX SA (ALCOX.PA) Stock Fundamental Analysis

EPA:ALCOX - FR0013018124 - Common Stock

0.323 EUR
+0.01 (+2.22%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, ALCOX scores 3 out of 10 in our fundamental rating. ALCOX was compared to 74 industry peers in the Biotechnology industry. ALCOX has a bad profitability rating. Also its financial health evaluation is rather negative. ALCOX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALCOX has reported negative net income.
In the past 5 years ALCOX always reported negative net income.
ALCOX had a negative operating cash flow in each of the past 5 years.
ALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of ALCOX (-92.83%) is worse than 75.68% of its industry peers.
ALCOX's Return On Equity of -653.37% is on the low side compared to the rest of the industry. ALCOX is outperformed by 72.97% of its industry peers.
Industry RankSector Rank
ROA -92.83%
ROE -653.37%
ROIC N/A
ROA(3y)-53.69%
ROA(5y)-42.4%
ROE(3y)-266.03%
ROE(5y)-174.79%
ROIC(3y)N/A
ROIC(5y)N/A
ALCOX.PA Yearly ROA, ROE, ROICALCOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

ALCOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCOX.PA Yearly Profit, Operating, Gross MarginsALCOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ALCOX has been increased compared to 1 year ago.
The number of shares outstanding for ALCOX has been increased compared to 5 years ago.
ALCOX has a worse debt/assets ratio than last year.
ALCOX.PA Yearly Shares OutstandingALCOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALCOX.PA Yearly Total Debt VS Total AssetsALCOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ALCOX has an Altman-Z score of -34.06. This is a bad value and indicates that ALCOX is not financially healthy and even has some risk of bankruptcy.
ALCOX has a worse Altman-Z score (-34.06) than 86.49% of its industry peers.
ALCOX has a Debt/Equity ratio of 4.40. This is a high value indicating a heavy dependency on external financing.
ALCOX has a Debt to Equity ratio of 4.40. This is in the lower half of the industry: ALCOX underperforms 70.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.4
Debt/FCF N/A
Altman-Z -34.06
ROIC/WACCN/A
WACCN/A
ALCOX.PA Yearly LT Debt VS Equity VS FCFALCOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ALCOX has a Current Ratio of 5.85. This indicates that ALCOX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALCOX (5.85) is better than 81.08% of its industry peers.
ALCOX has a Quick Ratio of 5.85. This indicates that ALCOX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.85, ALCOX belongs to the top of the industry, outperforming 82.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.85
Quick Ratio 5.85
ALCOX.PA Yearly Current Assets VS Current LiabilitesALCOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.81% over the past year.
The Revenue has grown by 13.86% in the past year. This is quite good.
Measured over the past years, ALCOX shows a small growth in Revenue. The Revenue has been growing by 2.77% on average per year.
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)13.86%
Revenue growth 3Y2.81%
Revenue growth 5Y2.77%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 48.32% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 102.03% on average over the next years. This is a very strong growth
EPS Next Y124%
EPS Next 2Y48.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year318.37%
Revenue Next 2Y102.03%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALCOX.PA Yearly Revenue VS EstimatesALCOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
ALCOX.PA Yearly EPS VS EstimatesALCOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALCOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 5.23, the valuation of ALCOX can be described as very cheap.
Based on the Price/Forward Earnings ratio, ALCOX is valued cheaper than 95.95% of the companies in the same industry.
ALCOX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.63.
Industry RankSector Rank
PE N/A
Fwd PE 5.23
ALCOX.PA Price Earnings VS Forward Price EarningsALCOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCOX.PA Per share dataALCOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

ALCOX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALCOX's earnings are expected to grow with 48.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.32%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALCOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NICOX SA

EPA:ALCOX (9/4/2025, 7:00:00 PM)

0.323

+0.01 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-21 2025-04-21
Earnings (Next)10-01 2025-10-01
Inst Owners6.33%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap23.42M
Analysts84.44
Price Target1.02 (215.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)128.57%
EPS NY rev (3m)128.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.23
P/S 2.98
P/FCF N/A
P/OCF N/A
P/B 7.81
P/tB 7.83
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.06
Fwd EY19.13%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.11
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.83%
ROE -653.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.69%
ROA(5y)-42.4%
ROE(3y)-266.03%
ROE(5y)-174.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 4.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.85
Quick Ratio 5.85
Altman-Z -34.06
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y124%
EPS Next 2Y48.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.86%
Revenue growth 3Y2.81%
Revenue growth 5Y2.77%
Sales Q2Q%N/A
Revenue Next Year318.37%
Revenue Next 2Y102.03%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A